Call Us: +91-779-979-0002/+91-779-979-0003

Plenary Talks

Abstract

There is consensus that only a preventive vaccine can contain the HIV/AIDS pandemic. After 30 years still there is no preventive HIV vaccine. Fundamental challenges to the development of a preventive HIV vaccine include the initially erroneous but enduring and powerful perception of the natural history of HIV disease, as an acute rather than a chronic illness even in the absence of therapy, the lack of appreciation of the quasispecies biology of HIV and the abandonment of principles of immunology theory caused by the allure of technological prowess. In addition two other important aspects will be analyzed. Since nearly 80% of sexually transmitted HIV infections are established by a single transmitted/founder virus (T/F), we will discuss the need to focus on vaccines directed against transmitted/founder viruses (T/F) and the reconsideration of HIV inactivation as a viable means to obtain a preventive HIV vaccine. Given the fact that T/F viruses evoke neutralizing antibodies (NAbs) of germline or unmutated common ancestors Abs (UCAs), we propose that highly mutated bNAbs resulting from chronic infection will not be needed if the initial T/F virus infection is prevented by evoking an effective immune response against T/F viruses. Specifically we will describe how potentially this objective can be achieved inactivating HIV by a targeted photo‐inactivation of HIV reverse transcriptase (RT). We propose the use of this novel and safe method, not available during the early years of the pandemic, to develop a T/F inactivated whole‐virus HIV vaccine.

Biography

Dr. Adan Rios is an Professor in the Division of Oncology at the University of Texas Health Science Center (UTHealth) McGovern Medical School. He received his medical degree from the University of Panama. He completed his fellowship in Medical Oncology at The University of Texas M.D. Anderson Cancer Center, where he served for a decade in a variety of roles, including director of clinical research and academic affairs of the AIDS Program at the Institute for Immunological Disorders, the first clinical center in the United States devoted to the management and treatment of AIDS patients. He is internationally renowned for his work in HIV-associated malignancies and treatment of tumors with biological response modifiers. He is a general oncologist with a special interest in lymphoma, leukemia and immune compromised related malignancies. Dr. Rios is fluent in Spanish and is actively involved with the Hispanic community. His work has been recognized with several awards and distinctions, among them, the 2001 MD Anderson Cancer Center Distinguished Alumnus Award, the 2003 George Washington University Presidential Medal Award and the 2008 University of Texas Health Science Center Minority Services Award for his efforts on behalf of the education of minority students in the science and health fields.

Speaker
Adan A. Rios / Professor,Department of Internal Medicine/ Division of Oncology
Texas

Abstract

There are many reasons for our inability to develop an HIV vaccine such as the enormous antigenic variability of the virus, the inability of the immune response in HIV-infected individuals to clear the infection and the ability of the virus to progressively destroy the immune system . Reductionist thinking had a negative impact on HIV vaccine development [1] because it made investigators confound chemical antigenicity with vaccine immunogenicity and led them to concentrate on the molecular structure of HIV vaccine immunogens instead of on the biological properties of immune systems that are responsible for the production of neutralizing antibodies [2,3]. Another main obstacle was that vaccinologists are unaware that the problems they try to solve are inverse problems . Most solvable scientific problems are direct problems that start with causes and make investigators study experimentally the resulting effects. Solving an inverse problem , however, starts with an effect and requires guessing what are the multiples causes that could have produced it . A vaccinologist , for instance , may start by developing a plausible model to explain the absence of deleterious HIV infection in elite controllers and would then have to demonstrate experimentally that when he adjusts certain parameters in human immune systems which the model says are crucial , he can obtain the desired protective outcome in a large population of genetically heterogeneous individuals [4]. Solving such an inverse problem usually fails because a theoretical model of a highly complex immune system never includes knowledge of all the relevant parameters needed to make an entirely rational decision. Furthermore , investigators have mainly studied the rather ineffective immune responses that occur after several years of chronic HIV infection , instead of analyzing the immune responses that occur in the initial acute phase of infection by T/F viruses which are more likely to be relevant for developing a preventive HIV vaccine [4]. References . [1] Van Regenmortel 2012, Front Immun 3:194. [2] Van Regenmortel 2014 , Front Immunol 5:593. [3] Van Regenmortel 2016, Int J Mol Sci 17:1591 [4] Van Regenmortel 2018 , Front Immunol 8: 2009.

Biography

Marc H V Van Regenmortel obtained his PhD at the University of Cape Town Medical School in 1961 and was in 1965-1966 an International Fellow in the US Public Health Service at the University of California in Berkeley. Subsequently he was a professor in Virology / Microbiology at several Universities in South Africa and France and , for 22 years , he directed the Immunochemistry Laboratory at the University of Strasbourg in the CNRS Molecular Biology Institute . In 2001 he became an Emeritus CNRS Research Director in Strasbourg He served (1984-1990) as Vice Chairman and Chairman of the Virology Division of the International Union of Microbiological Societies (IUMS) and was Secretary General of IUMS from 1990 to 1999. He was also for six years (1996-2002) President of the International Committee on Taxonomy of Viruses. He was for ten years a member of the international advisory board of the South African Aids Vaccine Initiative (SAAVI) and of the Institute of Microbiology and Molecular Medicine at the University of Cape Town. In 1995-2005 , he was a member of the board of directors of the biosensor company BIACORE in Uppsala , Sweden He has supervised the research work of 30 PhD students and published 400 research and review papers as well as a dozen books in the fields of Virology and Immunochemistry. He is currently Editor-in-Chief of Journal of Molecular Recognition and previously of Archives of Virology and Journal of AIDS & Clinical Research. He is also an Associate Editor of Advances in Virus Research, Analytical Biochemistry, Frontiers in Immunology, Journal of Immunological Methods and Bionomina. In 2008 , he co- edited with Brian Mahy of the CDC, the 3rd edition of the Encyclopedia of Virology in five volumes published by Elsevier. His h-index is 51.

Speaker
Marc H V Van Regenmortel / University of Strasbourg
France

Abstract

Current anti-retroviral therapy (ART) consists of 3 or 4 drug regimens and has evolved over the past 20+ years as standard of care (SOC) in treating patients. Indeed, from 20+ pills per day current SOC has now been reduced to as little as one pill once a day with very high efficacy and generally excellent tolerability and improved safety profiles. This tremendous advancement in ART has also resulted in improved adherence ensuring sustained viral suppression, reduced treatment failure thus ameliorating the chance of emergent drug resistance that may impact future treatment options. As a result, when given access to the latest ART, patients are now living much longer and therefore will need to take ART for decades. Consideration, therefore, must be given to reducing cumulative drug exposure and potential toxicity while maintaining viral suppression. Because of the availability of new and better antiretroviral drugs (ARVs), perhaps fewer ARVs can be given to reduce the potential long-term cumulative drug toxicity. In addition, fewer drugs might also mean lower cost thus the potential for improving access. Two drug regimens (2DR) have been investigated for many years with different drug combinations and inconsistent results with the following conclusion: 2DRs have just not been as good as SOC. However, there has been encouraging evidence over the past couple of years evaluating the integrase inhibitor, dolutegravir, in combination with either lamivudine or rilpivirine suggesting perhaps that 2DRs might, in fact, be as good as SOC. Perhaps even more exciting is the use of the long-acting injectable ARVs cabotegravir (another integrase inhibitor) and the non-nucleoside reverse transcriptase inhibitor, rilpivirine, that might be able to be given not on a daily basis, but perhaps every 4-8 weeks. This talk will focus on the evolution of ART from multiple ARVs to single-pill regimens, why until recently the use of 2DRs has not been as good as the current 3-4 drug regimens, and suggest that we may be approaching an era where 2 drugs may be as good as 3, and, may not have to be taken on a daily basis: true paradigm shifts.

Biography

With a career long dedicated to HIV patient care and clinical research, Dr Corklin (Corky) Steinhart enhances his role at ViiV Healthcare with more than 25 years of HIV experience. Having founded a multi-physician practice focused on specialty care for those living with HIV, Corky’s expansive HIV knowledge and solid clinical skills complement his leadership role in responding to ViiV’s global medical and scientific needs, and he and his team of medical experts provide critical input into attaining ViiV’s goals of HIV innovation and treatment access.
Current Role: Corky is currently Head of ViiV’s Global Medical Directors team, where he directs a team of ViiV experts in providing worldwide scientific and medical expertise and governance for ViiV initiatives. This includes oversight of the team’s involvement in ViiV-sponsored clinical trials, investigator-sponsored research opportunities, patient access programs, and medical and safety topics.
Experience: Prior to his current role with ViiV, Corky served since 2013 as ViiV’s Global Medical Lead for Triumeq, a single tablet HIV therapy. Before that, he held a number of Medical Affairs positions in the HIV and hepatitis C therapeutic areas for seven years at Merck. Before joining industry, Corky founded Steinhart Medical Associates in 1991 in Miami, Florida as a medical practice specializing in HIV care. By the time Corky left the practice in 2006, he was caring for more than 750 HIV positive patients and the practice had expanded to include four physicians providing care to a total of more than 2300 HIV positive patients. During his time at Steinhart Medical Associates, Corky also founded and served as Medical Director of Special Immunology Services at Mercy Hospital in Miami, FL, and served as Chairperson of the hospital’s Institutional Review Board. In addition, he was Medical Director of the Florida Caribbean AIDS Education Training Center. Over the years, Corky has conducted numerous HIV studies, served on multiple pharmaceutical advisory boards, lectured both nationally and internationally, and published extensively.
Education: Corky earned his MD degree in 1986 from the University of South Florida College of Medicine in Tampa, and a PhD in Cardiovascular Physiology in 1981 from Johns Hopkins University. He completed his postgraduate training at the University of Miami Jackson Memorial Hospital.

Speaker
Corklin R. Steinhart / Global Medical Directors at ViiV Healthcare
Florida

Keynote Talks

Abstract

BACKGROUND HIV infection in children is becoming a common occurence with prevalence of 0.3% and perinatal transmission being the most commmone mode of aquiring HIV among children. HIV is a multisystemic disorder and Mucocutaneous manifestations can be taken as marker of declining CD4 counts. This hospital based observational study was planned to study various mucocutaneous manifestations in HIV infected children and it's correlation with CD4 count. MATERIALS AND METHODS 102 HIV positive children between age of 18 month to 18 years attending pediatric HIV clinic of PGIMER and Dr RML Hospital, New Delhi were screened for mucocutaneous manifestations and clinical details were obtained using a performa. Appropriate laboratory investigations for diagnosing various dermatological manifestations were used to confirm the diagnosis. Also CD4 count and various biochemical tests were done. Statistical testing was conducted with statistical package for the social science system version SPSS 21.0. For all statistical test a p- value less than 0.05 were taken to indicate a significant difference. RESULTS Mean age of cases were 10.54 +/- 3.58 years with male preponderance. Majority of cases were in stage I (97.6%). 99% of patients were on HAART with 71.9% patients having CD4 count more than 500. Mucocutaneous manifestations were present in 16.7 % of patients with infectious dermatoses (76 %) being more commoner than non- infectious. CONCLUSION This observational study designed to evaluate various mucocutaneous manifestations and it's correlation with CD4 count, found low prevalence of mucocutaneous manifestations among the study group. This is attributed to higher CD4 count among HIV infected children due to good adherence to HAART. Mucocutaneous manifestations were present in patients with lower CD4 count.

Biography

Alok Hemal professor, department of pediatrician pgimer, dr. Ram Manohar Lohia Hospital New Delhi present affiliation Pgimer Dr. Ram Manohar Lohia Hospital New Delhi Major Achievements: (honours) (awards)(publications)special interest in Hemato-oncology & pediatric hiv. He is national convenor pediatric HIV Indian Academy of Pediatrics. He has certificate of completion of specialist training from Royal College of Pediatric & Child Health (RCPCH), London Uk. He has more then 50 research publications in national & international journals. Furthermore, he has many presentations in national & international conferences.

Speaker
Alok Hemal / Ram Manohar Lohia Hospital India

Abstract

Long acting, injectable, progestin-only hormonal contraceptives are used by about 20 million women in Sub-Saharan Africa, correlating with a high prevalence of HIV-1 infection. The predominant contraceptive used in Sub-Saharan Africa is the three-monthly intramuscular injectable contraceptive depo-medroxyprogesterone acetate (DMPA-IM). Clinical observational data suggest a significant association between DMPA-IM use and increased risk of HIV-1 acquisition, raising important concerns. No such association is detected for combined oral contraceptives (COCs) containing the progestin levonorgestrel, nor for the two-monthly injectable contraceptive norethisterone enanthate (NET-EN), although data for NET-EN are limited. Progestins are synthetic progestogenic compounds designed to act like progesterone via the progesterone receptor. Many different progestins are widely used at different doses in contraception and hormone replacement therapy. However, these progestins exhibit different degrees of cross-reactivity towards other members of the steroid receptor family of proteins, in a dose-dependent manner, possibly accounting for different side-effects. Susceptibility to HIV-1 may depend on the type of progestin and dose and method of delivery of the contraceptive formulation. MPA, unlike other progestins and progesterone, binds to and has relatively potent activity via the glucocorticoid receptor, which regulates multiple physiologically processes, including immune function. Susceptibility to HIV-1 has also been linked to higher progesterone levels in the luteal phase of the menstrual cycle. Several underlying biological mechanisms that may mediate the effect of progestins and luteal phase hormones on HIV-1 acquisition have been identified in clinical, animal, and ex vivo studies. These mechanisms and recent findings from the author’s laboratory will be discussed.

Biography

Janet Hapgood’s research group focuses broadly in intracellular molecular mechanisms of action of steroid receptors, in particular the glucocorticoid receptor (GR). In particular, it is focussed on ligand-selectivity, regulation of gene expression as well as cross talk between steroid receptors and other signalling pathways, which allows functional integration between stress, reproduction and immune function. This research is conducted in the broad context of reproduction, inflammation, contraception and infectious disease, in particular HIV-1. Most recently her lab has focussed on investigating the mechanisms and effects on immune function and HIV-1 pathogenesis of different progestin contraceptives via the GR, as well as cross talk between the GR and other receptors, and the role of the unliganded GR.

Speaker
Janet Patricia Hapgood / University of Cape Town South Africa

Abstract

There is increasing evidences that favor the prenatal beginning of schizophrenia. These evidences point toward intra-uterine environmental factors that act specifically during the second pregnancy trimester producing a direct damage of the brain of the fetus [1]. The current available technology doesn't allow observing what is happening at cellular level since the human brain is not exposed to a direct analysis in that stage of the life in subjects at high risk of developing schizophrenia. Methods. In 1977 we began a direct electron microscopic research of the brain of fetuses at high risk from schizophrenic mothers in order to finding differences at cellular level in relation to controls. Results. In these studies we have observed within the nuclei of neurons the presence of complete and incomplete viral particles that reacted in positive form with antibodies to herpes simplex hominis type I [HSV1] virus, and mitochondria alterations [2]. Conclusion. The importance of these findings can have practical applications in the prevention of the illness keeping in mind its direct relation to the aetiology and physiopathology of schizophrenia. A study of the gametes or the amniotic fluid cells in women at risk of having a schizophrenic offspring is considered. Of being observed the same alterations that those observed previously in the cells of the brain of the studied foetuses, it would intend to these women in risk of having a schizophrenia descendant, previous information of the results, the voluntary medical interruption of the pregnancy or an early anti HSV1 viral treatment as preventive measure of the later development of the illness. 1. Yolken RH, Torrey EF. Viruses, schizophrenia and bipolar disorders. Clin Microbiol Rev 1995; 8: 131-145. 2. Mesa CS. An ultrastructural study of the temporal lobe and peripheral blood in schizophrenic patients. Rev Neurol 2001; 33: 619-623.

Biography

Segundo Mesa Castillo. As Specialist in Neurology, he worked for 10 years in the Institute of Neurology of Havana, Cuba. He has worked in Electron Microscopic Studies on Schizophrenia for 32 years. He was awarded with the International Price of the Stanley Foundation Award Program and for the Professional Committee to work as a fellowship position in the Laboratory of the Central Nervous System Studies, National Institute of Neurological Diseases and Stroke under Dr. Joseph Gibbs for a period of 6 months, National Institute of Health, Bethesda, Maryland, Washington D.C. USA, June 5, 1990. At present he is member of the Scientific Board of the Psychiatric Hospital of Havana and give lectures to residents in psychiatry.

Speaker
Segundo Mesa Castillo / Institute of Neurology Cuba

Abstract

Plasmacytoid dendritic cells (pDC) are the major type I interferon (IFN-I) producing cells and play important roles in antiviral immune responses during acute virus infection. However, sustained pDC activation and IFN-I induction has been correlated with disease progression in chronic virus infection. We have recently functionally defined the HIV-pDC-IFN axis in HIV-1 immunopathogenesis, and studied the mechanisms of pDC/IFN-induced immune suppression, and its role in HIV reservoir persistence. We have discovered that blocking the pDC/INF-I axis during HIV infection reverses all HIV-related diseases even in the presence of higher levels of HIV replication. We further show that low levels of pDC/IFN-I signaling contribute to the immune dysfunction and foster HIV-1 persistence in cART-treated hosts. Transient depletion of pDC or blocking IFNAR during suppressive ART has been shown to provide a novel strategy to enhance immune recovery and to control HIV-1 reservoirs. Our findings thus not only functionally reveal the role of pDC/IFN-I in HIV-1 and other inflammatory diseases, the IFNAR blocking and pDC-depleting mAb will also be developed into novel therapeutics to enhance immune recovery to treat HIV-associated diseases and cancers.

Biography

His laboratory studies the virology, immunology and therapy of HIV-1 and HBV persistent infection. He currently focus on viral factors that interact and counteract host innate anti-viral immunity, and on how human immune cells are dysregulated and contribute to diseases during HIV-1 and HBV infection. He have developed various mouse models including humanized mouse models with human immune and liver cells to study human immunopathology of chronic HIV-1 and HBV infection in vivo. Regarding HIV-1 infection, He currently focus on the HIV-1/pDC/IFN-I axis that plays a critical role in AIDS progression. He also study HBV virology and the HBV-Macrophage/stellate cell axis in HBV-induced liver diseases. In addition, He is developing novel immune modulatory therapeutics including antibodies, adjuvants and vaccines.

Speaker
Lishan Su / University of North Carolina United States

Abstract

Background: HIV/AIDS leads to severe impairment in the health-related QOL for the patients. Antiretroviral therapy (ART) reduces morbidity and mortality due to AIDS. With reduced mortality and longer survival, quality of life (QOL) becomes an important goal of treatment. Optimizing ART to restore CD4 count and provision of social support to AIDS patients may improve their QOL. Objective The objective of the study are to assess the social support and quality of life of PLWA receiving antiretroviral therapy at BPKIHS; to find out the association of Quality of life and Social Support of people living with AIDS and selected variables and to find out the relationship between Quality of life of PLWA and social support. Material & Methods: Descriptive cross-sectional research design was used for this study among PLWA receiving ART at ART Clinic, BPKIHS. Total 90 PLWA were selected by convenient sampling technique. Data was collected by both qualitative and quantitative method through interview questionnaire and focus group discussion. Data were analyzed using SPSS version 20.0. Results: The study demonstrated that the mean age of respondents was 38.40 ± 8.80 and half of them (54.4%) were female. Mean score of overall QOL (62.74 ± 17.4) and social support (69.50 ± 18.50) were found to be higher .Overall QOL score was significantly associated with gender and educational status and overall social support score was significantly associated with gender and employment at 0.05 level of significance. There was significant positive relationship between overall score of social support and overall score of quality of life (r= 0.07, p= <0.001) at 0.01 level of significance. Conclusion: Based on the results, it can be concluded that more than half of the subjects had high QOL. Similarly, more than two-third of the subjects had good social support. Male sex and employed PLWA got good social support. There was positive relationship between QOL and Social Support. Thus, increase or decrease in social support tends to increase or decrease Quality of Life respectively. Key words: Quality of life, Social support, HIV/AIDS, PLWA Biography: Prof. Dr. Ram Sharan Mehta is Head of Medical-Surgical Nursing Department in College of Nursing, B. P. Koirala Institute of Health Sciences Nepal. I am involved in teaching Medical-Surgical Nursing for more than 20 years. I am involved in teaching the Nursing Education to the undergraduate and post graduate nursing students. I am the research committee member of this institute and actively involved in the guiding the undergraduate and post graduate nursing students

Biography

Prof. Dr. Ram Sharan Mehta is Head of Medical-Surgical Nursing Department in College of Nursing, B. P. Koirala Institute of Health Sciences Nepal. I am involved in teaching Medical-Surgical Nursing for more than 20 years. I am involved in teaching the Nursing Education to the undergraduate and post graduate nursing students. I am the research committee member of this institute and actively involved in the guiding the undergraduate and post graduate nursing students.

Speaker
Ram Sharan Mehta / BP Koirala Institute of Health Sciences Nepal

Abstract

Introduction We have applied High Resolution Melting Analysis (HRMA) for the genotyping of the Chlamydia trachomatis (CT) and applied it specifically to the 14 sexually transmitted infection-related genotypes: A-C, D-K, and L1-L3. Based on the genotype of the OMP1 (Outer Membrane Protein) gene CT is grouped into different serovars, which present in different clinical manifestations; with type A, B, Ba, and C causing trachoma, D-K cause urogenital infections and LI, LII & LIII associated with lymphogranuloma venereum(LGV). The OMP1 is one of the conserved genes found in CT. The aim of this study is to evaluate the prevalence of the above mentioned serovars. Methods Two hundred and sixty-five EswabTM clinical samples were screened for CT using Anyplex™ II STI-7 Detection. We confirmed the presence of the OMP1 gene with the conventional PCR. HRMA was performed to identify the CT serovars on a Quantstudio 5 qPCR instrument and CDC controls were included in the analysis. HRM analysis was done on the High-Resolution Melt Software v3.1. Results Using HRM we identified the following serovars A, B, C, D, E, F, G, I, J, L3. The highest prevalent serovars were serovar F = 29%; E = 16.1%; I = 12.9%; D and G both = 9.7% and the rest below 6.5%. No serovars: H, K, L1, L2 were identified. These are the preliminary results which should be validated using sequencing to confirm each genotype. In conclusion, serovars from D-K in this study dominate, with F being the most prevalent one. This serovar set has been associated with urogenital infections. HRM genotyping could be used to differentiate multiple concurrent urogenital CT infections in the clinical samples.

Biography

Thobile N. Khanyile is a Medical Intern Scientist at Inkosi Albert Luthuli Central Hospital (NHLS), where she is training to be a qualified Medical Scientist and register with HPCSA. The program started in March, 2018 and will end in March, 2020. I am currently due to finish my Masters in Medical Microbiology at University of KwaZulu Natal (UKZN). I studied Medical Science (Physiology) degree and did my postgrad degree (Honors) in Medical Microbiology at UKZN, 2012 and 2013, respectively. I started my Masters degree (Medical Microbiology) in 2016, my focus is on the STIs (mainly Chlamydia trachomatis) since they are the burden in health department as they also enhance HIV/AIDS transmission and causes other serious sequelae. I have attended FIDSSA 2017 conference to do poster presentation in Cape Town. I have worked as a Medical Research Assistant for a period of one year, where I was involved in different studies that were running in the laboratory (IACH-NHLS) and trained in diagnostic laboratory. I got to work with different professions that are experience in the laboratory and became fluent with the laboratory procedures. Joining NHLS will make me accomplish my dream of becoming a qualified scientist and involve myself in both diagnostic and research work. I believe in working hard and following your dreams no matter what the circumstances. My dream is to have good impact and inspire young individuals.

Speaker
Thobile Khanyile / University of KwaZulu Natal South Africa
Sessions:HIV & AIDS 2019

Abstract

The STD issues have always been connected with the obstinate behaviour of mankind. At times when it was not quite clear how STDs are contracted, people would consider that their triggers would be long trips overseas or wars, whereby we know today that those are just factors facilitating the spreading of STDs. The world’s oldest profession is connected with a serious risk of spreading this type of diseases. The diagnostics and therapy of a sexually transmitted disease sometimes resembles a detective story. There also are cases where the patient is misdiagnosed and gets to see a dermatologist only after their disease has advanced. Sometimes, even a laboratory examination provides us with false information. The presentation presents some cases of false TPHA positivity, syphilis infection contracted at a defloration, non-diagnosed ulcus durum treated as pyoderma, relapsing viral genital infections or scabies in prostitutes. As well as accidental identification of the patient with HIV prior to his inclusion in a clinical trial for other dermatoses. The last patient is the proof of the so- "hidden patients"

Biography

Hana Zelenková has been active in the field of Dermatovenerology since 1973. Since 2000 she has been directing her own Private Clinic of Dermatovenereology. Professional orientation: aesthetic dermatology, acne and facial dermatoses, medicinal mycology (nail diseases), wound management, psoriasis, employment of Ichthyol and carboxytherapy in dermatology. She is a coordinator of many international multicentre trials. More than 555 expert lectures in the Slovak Republic as well as abroad, 440 scientific publications. Co-author of the dermatocosmetic formulae containing Ichthamol and glycyrrhizinic acid. Author of the book “Carboxytherapy” (2015), translated into 4 languages. Regularly invited to deliver lectures at international congresses. Founder and President of the Slovak Society for Aesthetic and Cosmetic Dermatology (SSEDK), organizer and President of the traditional international DERMAPARTY congress. Since 2006 Vice-President European Society of Aesthetic and Cosmetic Dermatology, since 2007 President of the European Society of Aesthetic and Cosmetic Dermatology

Speaker
Hana Zelenková / Vice-President European Society Slovak Republic

Abstract

Background: HIV/AIDS leads to severe impairment in the health-related QOL for the patients. Antiretroviral therapy (ART) reduces morbidity and mortality due to AIDS. With reduced mortality and longer survival, quality of life (QOL) becomes an important goal of treatment. Optimizing ART to restore CD4 count and provision of social support to AIDS patients may improve their QOL. Objective The objective of the study are to assess the social support and quality of life of PLWA receiving antiretroviral therapy at BPKIHS; to find out the association of Quality of life and Social Support of people living with AIDS and selected variables and to find out the relationship between Quality of life of PLWA and social support. Material & Methods: Descriptive cross-sectional research design was used for this study among PLWA receiving ART at ART Clinic, BPKIHS. Total 90 PLWA were selected by convenient sampling technique. Data was collected by both qualitative and quantitative method through interview questionnaire and focus group discussion. Data were analyzed using SPSS version 20.0. Results: The study demonstrated that the mean age of respondents was 38.40 ± 8.80 and half of them (54.4%) were female. Mean score of overall QOL (62.74 ± 17.4) and social support (69.50 ± 18.50) were found to be higher .Overall QOL score was significantly associated with gender and educational status and overall social support score was significantly associated with gender and employment at 0.05 level of significance. There was significant positive relationship between overall score of social support and overall score of quality of life (r= 0.07, p= <0.001) at 0.01 level of significance. Conclusion: Based on the results, it can be concluded that more than half of the subjects had high QOL. Similarly, more than two-third of the subjects had good social support. Male sex and employed PLWA got good social support. There was positive relationship between QOL and Social Support. Thus, increase or decrease in social support tends to increase or decrease Quality of Life respectively. Key words: Quality of life, Social support, HIV/AIDS, PLWA

Biography

Prof. Dr. Ram Sharan Mehta is Head of Medical-Surgical Nursing Department in College of Nursing, B. P. Koirala Institute of Health Sciences Nepal. I am involved in teaching Medical-Surgical Nursing for more than 20 years. I am involved in teaching the Nursing Education to the undergraduate and post graduate nursing students. I am the research committee member of this institute and actively involved in the guiding the undergraduate and post graduate nursing students.

Speaker
Ram Sharan Mehta / BP Koirala Institute of Health Sciences Nepal

Abstract

With poor uptake of HTS as a major factor limiting effective HIV prevention, demand creation for became key in Nigeria. Knowledge of HIV transmission by UNAIDS indicators was 25.4%, while 15.7% have tested for HIV; HTS was not accessible to 77.2% who need/desire to get tested (NARHS 2012). SURE-P supported NACA to bridge service uptake gaps & promote greater responsibility for HIV response. To promote HIV awareness and create demand for HTS uptake via community mobilisation & preventive messages reaching 90,000 persons in 30 states; provide linkage to other services via multi disease medical outreach. Increasing knowledge of HIV & uptake of HTS was prioritized; entry/advocacy meetings with community stakeholders; orientation for national programmers & local teams; community mobilization using community leaders and community media to share the benefits of HIV services uptake as a desired behaviour. IEC materials distributed; audio messages in local dialects also played a major role at venues to generate demand. Huge gains recorded with changes in HIV related knowledge, attitudes & practices among people. Advocacy efforts reached 1500 stakeholders all levels. HIV prevention messages reached 327,000 (community sensitization), 4,173,612 (local radios - using reach indexes of local stations), 39,162 (IPC); 112,267 persons tested for HIV (24.7% above the target - 90,000), in addition to checks/tests for blood glucose, BMI, temperature, BP & malaria, with free drugs; (hematinic, antimalarial drugs, antihypertensive drug, analgesics. etc). 1,179,006 condoms & 900,531 free LLITN distributed. 3million people were reached with HIV prevention information via IECs. With changing climate in donor funding for SBCC intervention for HIV services in Nigeria there is a very exigent need for donor/government funding inorder to sustain gains of HTS demand creation efforts, which is a key feature of the NSF 2015 - 2022 for prioritized HTS at community levels.

Biography

Kingsley Essomeonu is a Social & Behaviour Change Communicator (SBCC) expert) with bias for HIV, TB & Malaria, trained and certified by John Hopkins University Centre for Communication Programs, USA under the tutelage of Dr. Ben Lozare, A graduate of Mass Communication with Masters in Sociology from University of Nigeria Nsukka, has completed Leadership for Management and Health from the department of Global E – Learning, University of Washington, USA. Kingsley as a founding member of the Global Youth Coalition on HIV/AIDS was part of USAID funded Planning for Life workshop – capacity development for International Youth Foundation USA & partners to integrate ARSH & FP into employability, leadership & education programs, New Delhi India in 2007. He’s an Assistant Chief Program Officer & Head Adolescents Young People Program in NACA.

Speaker
Kingsley Essomeonu / John Hopkins University Center for Communication Programs, USA

Abstract

Since 1995, I am proposing that the most effective and 100% effective solution of the preventive HIV / AIDS vaccine is found in the proteins of cockroaches. Once and for all we must understand that our physical body will continue to develop its immune capacity and will become stronger and more resistant as we assimilate diseases, viruses and bacteria. In other words, the same thing that makes us sick is the same thing that heals us, a statement by Luis Pasteur. Approaches and solutions: Cockroaches are the oldest and most powerful living beings on the face of the earth. It is estimated that they can be 350 to 400 million years old. They have survived great cataclysms, atmospheric phenomena and also atomic bombs. Their bodies have symbionts, organisms that allow them to coexist for their benefit with viruses and bacteria and in the same way, our human body coexists with viruses and bacteria. There are thousands of varieties of cockroaches, but specifically those that live in the sewers and feed on vaginal waste, semen, feces and excrement: "La Periplaneta" is the variety that I am proposing that we use for research. I give as an example the method used by the doctor and rural poet Eduardo Jenner in 1776. He used the milk serum of the cows to create the antibodies and solve the human smallpox vaccine. In the case of the HIV / AIDS preventive vaccine, I am proposing that we use the cockroach proteins for the same purpose and as the only solution. For logical reasons of observation, science has already proven that cockroaches are the most powerful living beings on the planet and I am proposing and proposing that we need to take their strength and power. I explain: strengthen our Immunological System (CD + 4 T lymphocytes) with cockroach proteins and create the antibodies to be able to resist and coexist with HIV. The CD + 4 T lymphocytes are the most powerful and highest-ranking cells of our immune system and it is precisely they who attract, receive and host the Human Immunodeficiency Virus (HIV). Process: First phase (1) .- Strengthen our immune system with small doses of cockroach proteins given every (40) forty days. Second phase (2) .- Reinforced, strengthened and vigorous our body; we will develop antibodies to be able to resist HIV. Third phase (3) .- We will inject the HIV virus or antigen preparation in an attenuated form, read, preventive HIV vaccine. I add the following note: the English scientist Dr. Dennis Burton, who works in the Department of Immunology and Microbial Sciences of the United States said in an international seminar in August 2010: "It is about creating a vaccine that creates antibodies in people All scientific efforts are aimed at creating antibodies that can fight the virus "... Scientific research confirms our approach: In September 2010, a group of scientists gathered at the University of Nottingham, England, confirmed the following: "Cockroaches, more than a risk to health, could become a rich source of antibiotics, according to new research." See the news in this Link: http://www.bbc.co.uk/mundo/ciencia_tecnologia/2010/09/100906_cucarachas_antibioticos_men.shtml In 2013: "The cockroach breeding boom in China". Three years ago, pharmaceutical companies began registering drugs based on cockroaches. Cockroach preparations are used as a traditional method of healing in China. This will strengthen the immune system. In addition, the cockroach powder allegedly helps fight breast cancer, says Professor Pu Sheban of the Medical University of Nanjing City. ORIGINALITY OF INNOVATION: Our research is based on discoveries and concepts that have already been approved and accepted by science. Simply what I have done is to string together the ideas and the findings; starting from the millennial Scientific Method. The healing power of cockroaches has its origins in Traditional Chinese Medicine. Now, our theoretical approach since 1995, in the proteins of cockroaches is the solution of the 100% effective preventive vaccine and the Santa Cucaracha Scientific Research Project, HIV / AIDS Vaccine, is our responsibility and is 100% original. We have Certificate of Registration of the National Copyright Office, Certificate of Registration of the National Office of Industrial Property, press publications, institutional communications of the United States Agency for International Development (USAID), website: htpp: //www.solargovernment.org and others that demonstrate and prove that it is an original idea and approach. See attached documents. Functionality of Innovation: The famous singer and trumpeter Louis Armstrong used to say that throughout his childhood he was given cockroaches for almost any illness. World Campaign of the United Nations Organization for Agriculture and Food (FAO). "Eat insects" is the original campaign launched in 2013 by the United Nations Organization for Agriculture and Food (FAO), after discovering through an important study that insects are nutritious, several, economic and even delicious. It is for this reason that the studies of some food agencies are thinking that insects could be the main source of protein in the human diet of the future. The entomophagy It is the intake of insects, arachnids or arthropods in general as food for humans, a food habit widespread in some cultures of the Earth. It is quite possible that insects were part of the human diet since ancient times, before tools for hunting and farming were developed. News published in 2013: The cockroach breeding boom in China. Three years ago, pharmaceutical companies began registering drugs based on cockroaches. Patients can take it or apply it on the skin up to three times a day. This will strengthen the immune system, stop infections and even help against chronic stomach ailments. In addition, the cockroach powder presumably helps fight against breast cancer and in the cosmetic industry is used against wrinkles. The products have an effect, says Professor Pu Sheban, from the Medicine University of Nanjing City. Cockroaches are known for their healing abilities in the tradition of Chinese medicine, says Professor Pu. Link: http://www.elcomercio.com/mundo/cucarachas-China-medicina-negocio_0_1015098686.html. ANOTHER IMPORTANT INVESTIGATION "The medicinal insects of Brazil" The healing power of cockroaches in various diseases. Link: http://www.sea-entomologia.org/PDF/GeneraInsectorum/GE-0060.pdf The Santa Cucaracha Scientific Research Project, HIV / AIDS Vaccine, has its origins in Traditional Chinese Medicine. There are few data available on the origin of Chinese Medicine, probably a long evolution that goes back to the night of time, we can say that it may be the oldest medicine that still exerted by the human being, being one of the most used medicines on the planet due to the extension of the Chinese people and its current boom and expansion throughout the world. The Chinese Medicine that we study today is a compilation of all the medical knowledge compiled during such a long journey, so we can imagine the amount of clinical experience accumulated in this time. Impacts of innovation: The agreements we have established in the Millennium Development Goals in the year 2000, within the framework of United Nations programs, specify that we have this term in 2015 to resolve these difficulties and continue to evolve as a Planet. Objective No 6 is the HIV AIDS. A preventive vaccine against HIV has the potential to control the global AIDS epidemic and prevent the suffering of millions of people. An estimated 38 million people are living with HIV worldwide, including 4 million children. AIDS has killed more than 32 million people since the beginning of the epidemic more than 30 years ago and 1.8 million people die every year. Approximately 6,000 people are infected with HIV every day, for a total of approximately 2.7 million new infections each year worldwide. If it continues to grow, it is estimated that in 10 years one in ten people will be infected with HIV. Prevention is not a solution, the solution is in the vaccine. Millions and millions have been spent on prevention programs and the nations budget will continue to increase. The funds to fight the epidemic have increased enormously in recent years around the world, we quote: (from US $ 1,600 million in 2001 to US $ 16,800 million in 2011). The Santa Cucaracha Scientific Research Project, HIV / AIDS Vaccine gives us the opportunity to find the solution to a great social and economic problem. Personal Commitment, Attitude, Persistence, Effort: The Scientific Research Project "Santa Cucaracha" HIV / AIDS Vaccine. A concept of art, science and society. I am Mariojosé Ángeles, a visual artist with more than twenty-five years of recognized local and international trajectory; specifically in Belgium and some European cities. Parallel to my career, in 1993, I voluntarily and independently began an investigation of the HIV / AIDS vaccine, with advice from the Former Secretary of State for Public Health of the Dominican Republic, Dr. Amiro Pérez Mera, ( deceased) friend of my family and who gives me the first book on HIV / AIDS. Two years later (1995), I traveled to the city of Guayaquil, Ecuador to fulfill commitments of exposure as an artist, but at the same time I was following up on my research on the vaccine. After hours and hours of reading books, encyclopedias, specialized magazines I came to the conclusion of the vaccine: "La Cucaracha". From that moment, a very strong anguish and a certain desperation took over me. Then I traveled from the city of Guayaquil to Quito for an interview with the Minister of Public Health, Dr. Alfredo Palacios and since I am not a doctor by profession, it was very difficult for me to be heard by qualified people specialized in medicine. At that time I was only 33 years old and the lack of experience caused me to provoke an almost fatal situation that ended with my imprisonment and then my deportation to the Dominican Republic, in the month of August of 1996. All this situation generated in my family and close friendships, a lot of worry and misunderstandings (the boy went crazy). From that experience, I continued my investigations but in a discreet way and keeping silence. I travel to Europe in 1998 and return to the country in 2007. During that time, I kept silent with the research, studied, collected information and only dedicated myself to my profession as a visual artist and also, I occupied the diplomatic functions as Cultural Attaché of the Embassy of the Dominican Republic before the Kingdom of Belgium and the European Community (2000-2004). In 2008, when I was in the country, I received an invitation to the Venice Biennale to present a project as an artist, and at that time I had taken up my vaccine research with strength, courage and determination and I said to myself; As I am not a doctor and what I am is an artist, we are going to create an art project and, through it, present the vaccine research. The idea was perfect and I present you with an installation project with huge cockroaches made of metal 2.40 meters high. The project was not approved in Venice and then presented to the León de Santiago Center and was not approved either. The name of the project "Santa Cucaracha" owes its name thanks to a publication dedicated by the editor of the newspaper El Día, Dr. Molina Morillo, dated March 24, 2008. Finally in 2009 we managed to present the "Santa Cucaracha" project at the Palace of Fine Arts of Santo Domingo, within the framework of the First International Art Fair in the Dominican Republic. From that moment the investigation took another turn. Research is not activity for pessimists or skeptics. I have had to develop tolerance, perseverance, tenacity, will, mental concentration in the study and tranquility of spirit in a spiritually stimulating and morally clean environment. Take care of good health, physical and mental resistance, good memory, optimism, initiative and I have worked with fervent enthusiasm. And something very important, has helped me cultivate good human and social relations. I have received support communications from USAID Santo Domingo, from the Bill and Melinda Gate Foundation, from the United States Bureau of Integrity, from Dr Anthony Fausi, director of the National Institute of Allergy and Infectious Diseases. Economic and Financial Viability of Innovation: We have received countless communications from the Bill and Melinda Gate Foundation and other institutions to present the project in a formal and institutional manner. In this sense, the phase in which the "Santa Cucaracha" HIV / AIDS Vaccine Research Project is located is the following: With the help and moral support of all sectors of Dominican society, we are creating the Solar Government Foundation. For this, we need economic and financial resources. And most importantly: the support of a qualified medical, scientific and administrative team to initiate investigations. At the moment, we have an open global campaign of education and awareness in favor of the HIV / AIDS Vaccine and the Scientific Research Project "Santa Cucaracha". My main cause is that governments, universities, scientists, researchers, doctors, vaccinologists, immunologists, virologists and specialists in infectious diseases raise awareness and start this research in their respective institutions around the world.

Biography

Mariojosé ANGELES, is one of the great visual artists from the Dominican Republic with international trajectory who is recognized for his struggle as an activist to find the preventive HIV/AIDS vaccine. He not a doctor graduated from a university of medicine. But, he is considered as researcher of the HIV vaccine from official institutions of United States and Europe. Mariojosé was born in Santo Domingo and studied architecture for 3 years at the Autonomous University of Santo Domingo (UASD), after he decided to study painting, his true passion. Today he lives and works in the Dominican Republic, where he has spent more than thirty years recognized career artistic, whose works has gone around the world having been well received especially in Belgium and some European cities, where he lived by nine years. Parallel to his career, in 1993, voluntarily and independently using the Millennial Scientific Method and began an investigation of the HIV/AIDS vaccine, with advice of the former Secretary of State for Public Health of the Dominican Republic, Dr. Amiro Pérez Mera, (deceased) who gave him the first book on HIV/AIDS. Two years later (1995), he traveled to Guayaquil, Ecuador to fulfill commitments of exposure as an artist, but at the same time he was following up his research of the vaccine. After hours and hours of reading books, encyclopedias, specialized magazines he came to a conclusion of the vaccine: "The proteins of cockroaches". Then he traveled from Guayaquil to Quito for an interview with the Minister of Public Health, Dr. Alfredo Palacios, and it was very difficult for him to be heard by qualified people specialized in medicine. Since 1995, he proposing that the most effective and 100% effective solution of the preventive HIV/AIDS vaccine is to be found in the proteins of cockroaches. Once and for all we must understand that our physical body will continue to develop its immune capacity and will become stronger and more resistant as we assimilate diseases, viruses and bacteria.

Speaker
Mariojosé ANGELES / University Autonomous of Santo Domingo Dominican Republic

Plenary Talks

Abstract

Acquired immunodeficiency syndrome (AIDS) is caused by two types of human immunodeficiency viruses HIV-1 and HIV-2, collectively known as HIV. The first stage is known as an “acute early phase” where the immune system has no specific antibody defense and the viral load is high, making a person highly infectious. Once the immune system begins producing antibodies following seroconvertion, infection enters a chronic phase, known as established infection. Subsequently, the immune system is slowly degraded and the individual becomes immunodeficient. When CD4 cell count is below 200 per microliter of blood regardless of the presence or absence of symptoms, is designated as having AIDS. Traditionally, majority of HIV diagnosis involves use of testing that involves antibody only detection, and do not detect the acute phase infection during which both the viral RNA and p24 antigen are expressed. Studies indicate that early diagnosis and treatment of HIV infection can improve survival, reduce medical costs, and reduce transmission of HIV to new uninfected partners. Newer 4th generation antigen/antibody combination (combo) tests are highly sensitive and specific for detection of both acute and established HIV infection (HIV-1 and HIV-2) enabling immediate linkage to care. The CDC (Center of Disease Control, USA) recommended a new test algorithm which calls for three different tests to screen and diagnose acute and established infections of HIV-1 and HIV-2 in a general population. Initially a 4th generation combo test detects a viral antigen p24 and specific antibodies against HIV -1 and HIV-2 envelope proteins. Positive results are then confirmed with an HIV-1/HIV-2 antibody differentiation immunoassay. If negative by this supplemental test, a nucleic acid test is used to determine if the patient has acute infection due to presence of p24 antigen but no antibodies. The advantage of this approach is to effectively reduce newer HIV transmission through immediate linkage to care and patient education following diagnosis.

Biography

Dr. De received PhD from University of Maryland, USA. Completed two postdoctoral studies at Cornell and Vanderbilt university. Professor De is currently the Division Chief of Clinical Chemistry and POCT laboratories. Published more than 68 peer reviewed articles and meeting abstracts. Received research grants from national and local agencies. Reviewer of national and international journals. Honored with Paul Finley Chemist Award. Served in American Board of Clinical Chemistry, Toxicology and Molecular Pathology. He was elected to be the chair of nominating committee of this board in 2016. Dr. De is the president elect, Rocky Mountain Division of American Association of Clinical Chemistry.

Speaker
Barun K De / University of Arizona
USA

Abstract

2. Introduction The world has about 2.3 and 2.5 billion Christians, roughly a third of the world population. Apparently religious leaders are underutilized in HIV and AIDS action to seriously chase down HIV transmission and stigma and scale up care and support. Like traditional leaders who could harness their subjects to keep HIV out of their villages, religious leaders could surely command the AIDS fight in their religious circumscriptions. 3. Methodology This study is both a documentary review and a survey. 50 articles sourced from Google using the search request “religious leaders in HIV prevention”, ranged from 2002-2016, fourteen years of research on the extent to which religious leaders participate to downscale HIV prevalence and enhance treatment, care and support. Each article was thoroughly scanned to ascertain religious leaders roles in HIV prevention in order to suggest how these religious leaders could be better utilized to plan, implement and evaluate HIV interventions. A survey of 10 districts in the North and Southwest regions of Cameroon ex-rayed issues surrounding the use of religious leaders in HIV business. 4. Findings In the 50 articles and documents consulted, 25 (50%) of these articles and documents showed that event though religious leaders are the fulcra in grassroots HIV preventive action, they are not often adequately and maximally used, 20(40%) said they would have loved to carry out health education and awareness on HIV and AIDS issues but they had neither the capacities nor the logistics while in 5(10%) of these papers reported that religious leaders had never had any training on HIV and AIDS. From all the articles scanned, the religious leader’s roles were identified. 4.1. Roles of Religious Leaders in HIV and AIDS Action 4.1.1. Influencing social and moral values/ traditions of the general public. 
 4.1.2. Increasing and influencing public knowledge and opinion. 
 4.1.3. Influencing and supporting political attitudes, opinions, policy and laws. 
 4.1.4. Reapportioning existing charitable resources for spiritual and social care and raising 
new financial resources for care and support. 
 4.1. 5. Promoting public HIV awareness action at the grassroots national levels. 
 4.1.6. Convincing people to live according to Quranic and Biblical HIV fee principles 4.1.7. Encouraging making HIV an open secret to allow people discuss related issues and problems and for patients to be regarded as sinners that might make them hide their status; failure to seek help and further spread the disease. 
 4.1.8. Helping PLWHA, live longer, more meaningful and dignified lives. 4.1.9. Informing people how to protect themselves and their loved ones from HIV. 4.1.10. Telling the general public how HIV spreads and how it can be treated 4.1.11. Helping the communities to tolerate and provide support to eradicate fear and stigma suffered by PLWHA. 4.1.12. Supporting promulgation of correct information about prevention based on religious principles 
4.1.13. Working for the promotion of religious values and marital fidelity by Including HIV/AIDS prevention messages in religious consultations for the eradication of violence against women, child abuse, drugs and intoxication. 4.1.14. To promote voluntary and confidential HIV testing and counseling services, the control of sexually transmitted diseases and their treatment, clean and safe deliveries, blood screening and the use of new needles. 4.1.15. To promote the provision of social and spiritual facilities, to HIV/AIDS affected people and to reach out to the most vulnerable to the disease because of their social and economic conditions. To give special attention to the needs of people living with HIV, or those affected by HIV and AIDS. 4.1.16. Work to prevent deterioration of economic and social conditions due to the HIV/ AIDS. Religious organizations should adopt better measures to generate resources and eradicate economic inequality with the collaboration of the government, NGOs, private institutions and social organizations. 4.1.17. Discussing HIV and AIDS issues in the context of political and social meetings, religious gatherings and religious institutions. 4.1.18. Spreading the facts and promote religious moral attitudes. Coordination forums can be established. 
 4.1.19. Teaching using Quranic and biblical teachings, other holy books, international documents on human rights, women and children’s rights especially to the vulnerable (elderly, the sick, the disabled, widows and orphans). 
 4.1.20. Discussing HIV and AIDS issues in national councils, established and existing institutes with Religious organizations being represented by their high level leadership. They should synergize with local, national and international organizations or establish new organizations to fight against stigma and discrimination and 
support positive government policies, national projects and budget proposals for HIV prevention and care. 
 4.1.21. Campaigning against HIV/AIDS at all levels of the health system to help eradicate hepatitis B and C. 4.2. Opinions of Religious Leaders Interviewed On the other hand of 30 religious leaders (N=25, 83%) at grassroots religious leaders that were interviewed within the CBC HS program in the Northwest and Southwest regions of Cameroon. 83%(N=25) said they are not well utilized in HIV prevention, 33% compared to that scanned from the articles and documents review. Their opinions are given below: 4.2.1. Religious leaders claimed that they were not involved in planning, coordination and implementation and evaluation meetings; 4.2.2. Heads of health centers were not treating them as important HIV stakeholders; 4.2.3. They were not regularly paid technical visits on HIV prevention and care; 4.2.4. Health and income generating projects were carried out in their church jurisdictions without their involvement; 4.2.3. They were not briefed on the type of information to collect and how to document and channel such information; 4.2.4. They were adequately incapacitated to conduct HIV/AIDS awareness and education but. 4.2.5. They were not: regularly invited to coordination and planning meetings. 5. Way Forward 5.1. Standardize HIV and AIDS approaches for action by religious leaders as core stakeholders. 5.2. Increase the capacity building based on evidence-based HIV prevention and action by churches. 5.3. Encourage churches to allow their religious leaders to preach the (ABCDEF , Amungwa, 2017) strategies of HIV and AIDS action. 5.3. Encourage inter-religious (ecumenical) collaboration to enhance the involvement of religious leader in HIV and action to scale down HIV prevalence and AIDS. 5.4. Influencing religious tradition to promote PLWHA and PABHA strategies that help them live longer and better lives. 5.5. Influencing the creation and adequate and maximal use of religious leaders networks that will enable them share knowledge and participate actively in HIV prevention strategies like PMTCT and IDU 5.6. Ensure mobilization, maintenance and reapportioning of charitable resources and spiritual and social care. 5.7. Raising new financial resources for care and support.

Biography

Amungwa Athanasius Nche is facilitate capacity development and performance through putting training, counseling, clinical and social skills at the disposal of institutions and individuals Certified Training Professional with substantial National and International expertise with English and French Language as evidenced by 20 years of experience. Capacity developer focused on health and development to promote high quality performance achievements as per set standards and norms. Training Manager able to design training deliverables with substantive national and international experience in training design, training delivery, monitoring and evaluation.including being able to carry out effective backstopping based on regular supervision outcomes. Peer Educationist with design, monitoring,evaluation and performance gap corrections skills and having valuable national and international experience inclusive of the UN. Clinician in the nursing, reproductive health and intensive care domains with considerable experience and innovative skills.

Speaker
Amungwa Athanasius Nche / Atanga Kidney Foundation
Nigeria

Abstract

Biography

Dr. Inungu holds a Doctor of Public Health degree from Tulane University and Doctor of Medicine from the University of Kinshasa, DR Congo. After several years in academia at Central Michigan University, he joined Population Services International as the Regional Researcher for West and Central Africa to oversee social marketing research in Benin, Burkina, DRC, Liberia and Nigeria. The research focuses essentially on the prevention of HIV, malaria, diarrhea, the promotion of hygiene and sanitation and reproductive health. He is also interested in program design and evaluation and capacity building. Specialties: Public health research, HIV/AIDS, Child Survival, M&E and Reproductive Health

Speaker
Joseph Inungu / Central Michigan University
USA

Sessions:

Abstract

Adolescents living with HIV is a global crisis. AIDS is the number one killer of adolescents 10-19 years of age in Africa and number two worldwide. There are 2.1 million adolescents living with HIV worldwide and every hour, 26 new infections are diagnosed. Within the 15-24 year olds, 380,000 new infections occur yearly with 60% being girls. In the United States, Men Who Have Sex With Men (MSM) accounted for 81% of youth diagnosed with HIV in 2016. Of those, 79% were young men of color living in southern part of United States. Gay and Transgender youth have a higher risk of HIV infection than their heterosexual counterparts and are subject to homophobia, trans-phobia and violence, therefore less likely to seek sexual health care. Located in a rural, isolated community in the south, we implemented a model which incorporates free rapid HIV testing, screening and treatment of Sexually Transmitted Infections (STI), PrEP and treatment for HIV positive youth and those at risk for infection in one clinic, focused on young gay men and transgender youth of color 15-30 years of age. Between 2016-2018, 92 youths (72 MSM, 2 transfemales, 7females, 10 males) were screened. Amongst MSM and transfemales, 9% (7/74) tested HIV positive, 19% (14/74) were treated for at least one STI. HIV negative youth were counseled and encouraged to start PrEP. Providing a non-judgemental, one-stop-shop for at risk young adults, provides an opportunity to decrease new HIV infections and stem the spread of HIV as well as other STIs.

Biography

Dr. Michelle Ogle obtained her Medical Degree from Wayne State School of Medicine in Detroit Michigan, USA. She also completed her residency and fellowship in Pediatric Infectious Diseases at Children’s Hospital of Michigan, USA. She is currently the Director at Warren-Vance Community Health Center, which provides medical care for youth living with HIV/AIDS in rural, North Carolina, USA. She is Pediatric liaison for the Pediatric Infectious Disease Society and HIV Medicine Association. She served as a member of the Presidential Advisory Council on HIV/AIDS under the Obama Administration and resigned in 2017 in protest of this administration’s posture towards PLWH.

Speaker
Michelle Collins Ogle / Warren-Vance Community Health Center USA

Abstract

Since 1995, I am proposing that the most effective and 100% effective solution of the preventive HIV / AIDS vaccine is found in the proteins of cockroaches. Once and for all we must understand that our physical body will continue to develop its immune capacity and will become stronger and more resistant as we assimilate diseases, viruses and bacteria. In other words, the same thing that makes us sick is the same thing that heals us, a statement by Luis Pasteur. Approaches and solutions: Cockroaches are the oldest and most powerful living beings on the face of the earth. It is estimated that they can be 350 to 400 million years old. They have survived great cataclysms, atmospheric phenomena and also atomic bombs. Their bodies have symbionts, organisms that allow them to coexist for their benefit with viruses and bacteria and in the same way, our human body coexists with viruses and bacteria. There are thousands of varieties of cockroaches, but specifically those that live in the sewers and feed on vaginal waste, semen, feces and excrement: "La Periplaneta" is the variety that I am proposing that we use for research. I give as an example the method used by the doctor and rural poet Eduardo Jenner in 1776. He used the milk serum of the cows to create the antibodies and solve the human smallpox vaccine. In the case of the HIV / AIDS preventive vaccine, I am proposing that we use the cockroach proteins for the same purpose and as the only solution. For logical reasons of observation, science has already proven that cockroaches are the most powerful living beings on the planet and I am proposing and proposing that we need to take their strength and power. I explain: strengthen our Immunological System (CD + 4 T lymphocytes) with cockroach proteins and create the antibodies to be able to resist and coexist with HIV. The CD + 4 T lymphocytes are the most powerful and highest-ranking cells of our immune system and it is precisely they who attract, receive and host the Human Immunodeficiency Virus (HIV). Process: First phase (1) .- Strengthen our immune system with small doses of cockroach proteins given every (40) forty days. Second phase (2) .- Reinforced, strengthened and vigorous our body; we will develop antibodies to be able to resist HIV. Third phase (3) .- We will inject the HIV virus or antigen preparation in an attenuated form, read, preventive HIV vaccine. I add the following note: the English scientist Dr. Dennis Burton, who works in the Department of Immunology and Microbial Sciences of the United States said in an international seminar in August 2010: "It is about creating a vaccine that creates antibodies in people All scientific efforts are aimed at creating antibodies that can fight the virus "... Scientific research confirms our approach: In September 2010, a group of scientists gathered at the University of Nottingham, England, confirmed the following: "Cockroaches, more than a risk to health, could become a rich source of antibiotics, according to new research." See the news in this Link: http://www.bbc.co.uk/mundo/ciencia_tecnologia/2010/09/100906_cucarachas_antibioticos_men.shtml In 2013: "The cockroach breeding boom in China". Three years ago, pharmaceutical companies began registering drugs based on cockroaches. Cockroach preparations are used as a traditional method of healing in China. This will strengthen the immune system. In addition, the cockroach powder allegedly helps fight breast cancer, says Professor Pu Sheban of the Medical University of Nanjing City. ORIGINALITY OF INNOVATION: Our research is based on discoveries and concepts that have already been approved and accepted by science. Simply what I have done is to string together the ideas and the findings; starting from the millennial Scientific Method. The healing power of cockroaches has its origins in Traditional Chinese Medicine. Now, our theoretical approach since 1995, in the proteins of cockroaches is the solution of the 100% effective preventive vaccine and the Santa Cucaracha Scientific Research Project, HIV / AIDS Vaccine, is our responsibility and is 100% original. We have Certificate of Registration of the National Copyright Office, Certificate of Registration of the National Office of Industrial Property, press publications, institutional communications of the United States Agency for International Development (USAID), website: htpp: //www.solargovernment.org and others that demonstrate and prove that it is an original idea and approach. See attached documents. Functionality of Innovation: The famous singer and trumpeter Louis Armstrong used to say that throughout his childhood he was given cockroaches for almost any illness. World Campaign of the United Nations Organization for Agriculture and Food (FAO). "Eat insects" is the original campaign launched in 2013 by the United Nations Organization for Agriculture and Food (FAO), after discovering through an important study that insects are nutritious, several, economic and even delicious. It is for this reason that the studies of some food agencies are thinking that insects could be the main source of protein in the human diet of the future. The entomophagy It is the intake of insects, arachnids or arthropods in general as food for humans, a food habit widespread in some cultures of the Earth. It is quite possible that insects were part of the human diet since ancient times, before tools for hunting and farming were developed. News published in 2013: The cockroach breeding boom in China. Three years ago, pharmaceutical companies began registering drugs based on cockroaches. Patients can take it or apply it on the skin up to three times a day. This will strengthen the immune system, stop infections and even help against chronic stomach ailments. In addition, the cockroach powder presumably helps fight against breast cancer and in the cosmetic industry is used against wrinkles. The products have an effect, says Professor Pu Sheban, from the Medicine University of Nanjing City. Cockroaches are known for their healing abilities in the tradition of Chinese medicine, says Professor Pu. Link: http://www.elcomercio.com/mundo/cucarachas-China-medicina-negocio_0_1015098686.html. ANOTHER IMPORTANT INVESTIGATION "The medicinal insects of Brazil" The healing power of cockroaches in various diseases. Link: http://www.sea-entomologia.org/PDF/GeneraInsectorum/GE-0060.pdf The Santa Cucaracha Scientific Research Project, HIV / AIDS Vaccine, has its origins in Traditional Chinese Medicine. There are few data available on the origin of Chinese Medicine, probably a long evolution that goes back to the night of time, we can say that it may be the oldest medicine that still exerted by the human being, being one of the most used medicines on the planet due to the extension of the Chinese people and its current boom and expansion throughout the world. The Chinese Medicine that we study today is a compilation of all the medical knowledge compiled during such a long journey, so we can imagine the amount of clinical experience accumulated in this time. Impacts of innovation: The agreements we have established in the Millennium Development Goals in the year 2000, within the framework of United Nations programs, specify that we have this term in 2015 to resolve these difficulties and continue to evolve as a Planet. Objective No 6 is the HIV AIDS. A preventive vaccine against HIV has the potential to control the global AIDS epidemic and prevent the suffering of millions of people. An estimated 38 million people are living with HIV worldwide, including 4 million children. AIDS has killed more than 32 million people since the beginning of the epidemic more than 30 years ago and 1.8 million people die every year. Approximately 6,000 people are infected with HIV every day, for a total of approximately 2.7 million new infections each year worldwide. If it continues to grow, it is estimated that in 10 years one in ten people will be infected with HIV. Prevention is not a solution, the solution is in the vaccine. Millions and millions have been spent on prevention programs and the nations budget will continue to increase. The funds to fight the epidemic have increased enormously in recent years around the world, we quote: (from US $ 1,600 million in 2001 to US $ 16,800 million in 2011). The Santa Cucaracha Scientific Research Project, HIV / AIDS Vaccine gives us the opportunity to find the solution to a great social and economic problem. Personal Commitment, Attitude, Persistence, Effort: The Scientific Research Project "Santa Cucaracha" HIV / AIDS Vaccine. A concept of art, science and society. I am Mariojosé Ángeles, a visual artist with more than twenty-five years of recognized local and international trajectory; specifically in Belgium and some European cities. Parallel to my career, in 1993, I voluntarily and independently began an investigation of the HIV / AIDS vaccine, with advice from the Former Secretary of State for Public Health of the Dominican Republic, Dr. Amiro Pérez Mera, ( deceased) friend of my family and who gives me the first book on HIV / AIDS. Two years later (1995), I traveled to the city of Guayaquil, Ecuador to fulfill commitments of exposure as an artist, but at the same time I was following up on my research on the vaccine. After hours and hours of reading books, encyclopedias, specialized magazines I came to the conclusion of the vaccine: "La Cucaracha". From that moment, a very strong anguish and a certain desperation took over me. Then I traveled from the city of Guayaquil to Quito for an interview with the Minister of Public Health, Dr. Alfredo Palacios and since I am not a doctor by profession, it was very difficult for me to be heard by qualified people specialized in medicine. At that time I was only 33 years old and the lack of experience caused me to provoke an almost fatal situation that ended with my imprisonment and then my deportation to the Dominican Republic, in the month of August of 1996. All this situation generated in my family and close friendships, a lot of worry and misunderstandings (the boy went crazy). From that experience, I continued my investigations but in a discreet way and keeping silence. I travel to Europe in 1998 and return to the country in 2007. During that time, I kept silent with the research, studied, collected information and only dedicated myself to my profession as a visual artist and also, I occupied the diplomatic functions as Cultural Attaché of the Embassy of the Dominican Republic before the Kingdom of Belgium and the European Community (2000-2004). In 2008, when I was in the country, I received an invitation to the Venice Biennale to present a project as an artist, and at that time I had taken up my vaccine research with strength, courage and determination and I said to myself; As I am not a doctor and what I am is an artist, we are going to create an art project and, through it, present the vaccine research. The idea was perfect and I present you with an installation project with huge cockroaches made of metal 2.40 meters high. The project was not approved in Venice and then presented to the León de Santiago Center and was not approved either. The name of the project "Santa Cucaracha" owes its name thanks to a publication dedicated by the editor of the newspaper El Día, Dr. Molina Morillo, dated March 24, 2008. Finally in 2009 we managed to present the "Santa Cucaracha" project at the Palace of Fine Arts of Santo Domingo, within the framework of the First International Art Fair in the Dominican Republic. From that moment the investigation took another turn. Research is not activity for pessimists or skeptics. I have had to develop tolerance, perseverance, tenacity, will, mental concentration in the study and tranquility of spirit in a spiritually stimulating and morally clean environment. Take care of good health, physical and mental resistance, good memory, optimism, initiative and I have worked with fervent enthusiasm. And something very important, has helped me cultivate good human and social relations. I have received support communications from USAID Santo Domingo, from the Bill and Melinda Gate Foundation, from the United States Bureau of Integrity, from Dr Anthony Fausi, director of the National Institute of Allergy and Infectious Diseases. Economic and Financial Viability of Innovation: We have received countless communications from the Bill and Melinda Gate Foundation and other institutions to present the project in a formal and institutional manner. In this sense, the phase in which the "Santa Cucaracha" HIV / AIDS Vaccine Research Project is located is the following: With the help and moral support of all sectors of Dominican society, we are creating the Solar Government Foundation. For this, we need economic and financial resources. And most importantly: the support of a qualified medical, scientific and administrative team to initiate investigations. At the moment, we have an open global campaign of education and awareness in favor of the HIV / AIDS Vaccine and the Scientific Research Project "Santa Cucaracha". My main cause is that governments, universities, scientists, researchers, doctors, vaccinologists, immunologists, virologists and specialists in infectious diseases raise awareness and start this research in their respective institutions around the world.

Biography

Mariojosé ANGELES, is one of the great visual artists from the Dominican Republic with international trajectory who is recognized for his struggle as an activist to find the preventive HIV/AIDS vaccine. He not a doctor graduated from a university of medicine. But, he is considered as researcher of the HIV vaccine from official institutions of United States and Europe. Mariojosé was born in Santo Domingo and studied architecture for 3 years at the Autonomous University of Santo Domingo (UASD), after he decided to study painting, his true passion. Today he lives and works in the Dominican Republic, where he has spent more than thirty years recognized career artistic, whose works has gone around the world having been well received especially in Belgium and some European cities, where he lived by nine years. Parallel to his career, in 1993, voluntarily and independently using the Millennial Scientific Method and began an investigation of the HIV/AIDS vaccine, with advice of the former Secretary of State for Public Health of the Dominican Republic, Dr. Amiro Pérez Mera, (deceased) who gave him the first book on HIV/AIDS. Two years later (1995), he traveled to Guayaquil, Ecuador to fulfill commitments of exposure as an artist, but at the same time he was following up his research of the vaccine. After hours and hours of reading books, encyclopedias, specialized magazines he came to a conclusion of the vaccine: "The proteins of cockroaches". Then he traveled from Guayaquil to Quito for an interview with the Minister of Public Health, Dr. Alfredo Palacios, and it was very difficult for him to be heard by qualified people specialized in medicine. Since 1995, he proposing that the most effective and 100% effective solution of the preventive HIV/AIDS vaccine is to be found in the proteins of cockroaches. Once and for all we must understand that our physical body will continue to develop its immune capacity and will become stronger and more resistant as we assimilate diseases, viruses and bacteria.

Speaker
Mariojosé ANGELES / University Autonomous of Santo Domingo Dominican Republic

Abstract

Scientific Research Project "Santa Cucaracha" HIV / AIDS Vaccine. Since 1995, I am proposing that the most effective and 100% effective solution of the preventive HIV / AIDS vaccine is found in the proteins of cockroaches. Once and for all we must understand that our physical body will continue to develop its immune capacity and will become stronger and more resistant as we assimilate diseases, viruses and bacteria. In other words, the same thing that makes us sick is the same thing that heals us, a statement by Luis Pasteur. Approaches and solutions: Cockroaches are the oldest and most powerful living beings on the face of the earth. It is estimated that they can be 350 to 400 million years old. They have survived great cataclysms, atmospheric phenomena and also atomic bombs. Their bodies have symbionts, organisms that allow them to coexist for their benefit with viruses and bacteria and in the same way, our human body coexists with viruses and bacteria. There are thousands of varieties of cockroaches, but specifically those that live in the sewers and feed on vaginal waste, semen, feces and excrement: "La Periplaneta" is the variety that I am proposing that we use for research. I give as an example the method used by the doctor and rural poet Eduardo Jenner in 1776. He used the milk serum of the cows to create the antibodies and solve the human smallpox vaccine. In the case of the HIV / AIDS preventive vaccine, I am proposing that we use the cockroach proteins for the same purpose and as the only solution. For logical reasons of observation, science has already proven that cockroaches are the most powerful living beings on the planet and I am proposing and proposing that we need to take their strength and power. I explain: strengthen our Immunological System (CD + 4 T lymphocytes) with cockroach proteins and create the antibodies to be able to resist and coexist with HIV. The CD + 4 T lymphocytes are the most powerful and highest-ranking cells of our immune system and it is precisely they who attract, receive and host the Human Immunodeficiency Virus (HIV). Process: First phase (1) .- Strengthen our immune system with small doses of cockroach proteins given every (40) forty days. Second phase (2) .- Reinforced, strengthened and vigorous our body; we will develop antibodies to be able to resist HIV. Third phase (3) .- We will inject the HIV virus or antigen preparation in an attenuated form, read, preventive HIV vaccine. I add the following note: the English scientist Dr. Dennis Burton, who works in the Department of Immunology and Microbial Sciences of the United States said in an international seminar in August 2010: "It is about creating a vaccine that creates antibodies in people All scientific efforts are aimed at creating antibodies that can fight the virus "... Scientific research confirms our approach: In September 2010, a group of scientists gathered at the University of Nottingham, England, confirmed the following: "Cockroaches, more than a risk to health, could become a rich source of antibiotics, according to new research." See the news in this Link: http://www.bbc.co.uk/mundo/ciencia_tecnologia/2010/09/100906_cucarachas_antibioticos_men.shtml In 2013: "The cockroach breeding boom in China". Three years ago, pharmaceutical companies began registering drugs based on cockroaches. Cockroach preparations are used as a traditional method of healing in China. This will strengthen the immune system. In addition, the cockroach powder allegedly helps fight breast cancer, says Professor Pu Sheban of the Medical University of Nanjing City.

Biography

Hana Zelenková has been active in the field of Dermatovenerology since 1973. Since 2000 she has been directing her own Private Clinic of Dermatovenereology. Professional orientation: aesthetic dermatology, acne and facial dermatoses, medicinal mycology (nail diseases), wound management, psoriasis, employment of Ichthyol and carboxytherapy in dermatology. She is a coordinator of many international multicentre trials. More than 555 expert lectures in the Slovak Republic as well as abroad, 440 scientific publications. Co-author of the dermatocosmetic formulae containing Ichthamol and glycyrrhizinic acid. Author of the book “Carboxytherapy” (2015), translated into 4 languages. Regularly invited to deliver lectures at international congresses. Founder and President of the Slovak Society for Aesthetic and Cosmetic Dermatology (SSEDK), organizer and President of the traditional international DERMAPARTY congress. Since 2006 Vice-President European Society of Aesthetic and Cosmetic Dermatology, since 2007 President of the European Society of Aesthetic and Cosmetic Dermatology

Speaker
Hana Zelenková / Vice-President European Society Slovak Republic

Abstract

Background: HIV/AIDS leads to severe impairment in the health-related QOL for the patients. Antiretroviral therapy (ART) reduces morbidity and mortality due to AIDS. With reduced mortality and longer survival, quality of life (QOL) becomes an important goal of treatment. Optimizing ART to restore CD4 count and provision of social support to AIDS patients may improve their QOL. Objective The objective of the study are to assess the social support and quality of life of PLWA receiving antiretroviral therapy at BPKIHS; to find out the association of Quality of life and Social Support of people living with AIDS and selected variables and to find out the relationship between Quality of life of PLWA and social support. Material & Methods: Descriptive cross-sectional research design was used for this study among PLWA receiving ART at ART Clinic, BPKIHS. Total 90 PLWA were selected by convenient sampling technique. Data was collected by both qualitative and quantitative method through interview questionnaire and focus group discussion. Data were analyzed using SPSS version 20.0. Results: The study demonstrated that the mean age of respondents was 38.40 ± 8.80 and half of them (54.4%) were female. Mean score of overall QOL (62.74 ± 17.4) and social support (69.50 ± 18.50) were found to be higher .Overall QOL score was significantly associated with gender and educational status and overall social support score was significantly associated with gender and employment at 0.05 level of significance. There was significant positive relationship between overall score of social support and overall score of quality of life (r= 0.07, p= <0.001) at 0.01 level of significance. Conclusion: Based on the results, it can be concluded that more than half of the subjects had high QOL. Similarly, more than two-third of the subjects had good social support. Male sex and employed PLWA got good social support. There was positive relationship between QOL and Social Support. Thus, increase or decrease in social support tends to increase or decrease Quality of Life respectively. Key words: Quality of life, Social support, HIV/AIDS, PLWA

Biography

Prof. Dr. Ram Sharan Mehta is Head of Medical-Surgical Nursing Department in College of Nursing, B. P. Koirala Institute of Health Sciences Nepal. I am involved in teaching Medical-Surgical Nursing for more than 20 years. I am involved in teaching the Nursing Education to the undergraduate and post graduate nursing students. I am the research committee member of this institute and actively involved in the guiding the undergraduate and post graduate nursing students.

Speaker
Ram Sharan Mehta / BP Koirala Institute of Health Sciences Nepal

Will be updated soon...